All the Active Ingredient Drugs
SNRI. Duloxetine HCl 30 mg, 60 mg. CAPS: 7,14,28 x 30 mg, 60 mg.
intial: 30 mg dly. maint: 60 mg dly.
Ther. response: 2-4 wks aft. tmt. To
discont: Taper by 1/2 dose (30 mg) dly
or on alt. days. See lit.
Major depress. episodes., Generalized
anxiety dis., Neuropath. pain assoc.
with diabet. periph. neuropathy.,
fibromyalg., chron. muscoskeletal pain.
C/I: Concom. use with MAOI,
uncontrolled narrow-angle glaucoma.
SNRI. Duloxetine 30 , 60 mg. CAPS.:30. For diabet. peripher. neuropath. pain: The usual dose is 60 mg ×1/d.
For chron. musculoskel. pain and general. anxiety disord.: For most pts.
60 mg ×1/d. Some pts. require an init. dose of Dulox Teva 30 mg ×1/d for one wk., and then the usual dose of
60 mg ×1/d.
For depression: Most pts. will receive 60 mg ×1/d. Some pts. require an init. dose of Dulox Teva 30 mg ×1/d for one wk., and then the usual dose of 60 mg ×1/d
Elderly – The init. dose of 30 mg ×1/d for two wks., and only then consider incr. the dose to 60 mg ×1/d.
Fibromyalgia: The init. dose of Dulox Teva is 30 mg ×1/d for one wk., and then the usual dose of 60 mg ×1/d. In most cases, the effect of medication ther. with Dulox Teva is noticeab. after 2-4 wks. of tmt.
See lit.
Tmt. of major depressive episodes.
Managem. of neuropath.pain associat. with diabet. peripher. neuropathy.
Tmt. of generaliz. anxiety disord. (GAD).
Manag. of fibromyalgia.
Manag. of chron. muscoskel. pain when other therapies have failed or are
contraindic. This has been establish. in studies in pts. with chron. low back pain (CLBP) and chron. pain due to osteoarthritis.
C/I: Hypersens.
Pts. with hep. dis.
Pts. with severe ren. dis..
Concom. use with MAOI includ. IV methylene blue and the antibiot.linezolid. MAOI should be discount. 14 d. before init.of the tmt. with duloxetine.
Initiat. of MAOI should be start. at least 5 d. after discount. of the tmt. with duloxetine.
Concom. use with thioridazine
SNRI. Duloxetine (HCl) 20, 40 mg. CAPS: 7,14,28,56X 20, 40mg.
Maint: 40 mg 2 x dly. Some pts. may
benefit from initial tmt. of 20 mg 2 x
dly for 2 wks bef. incr. to 40 mg 2 x dly.
Ther. response: Within 2-4 wks. To
discont. taper by 1/2 dose to either 40
mg 1 x dly or 20 mg 2 x dly.
Mod. to severe Stress Urinary Incontinence.
C/I: Hypersens., hepat. impair., pregn.,
lact. Not to be used in comb. with
nonselect. irrevers. MAOI’s or CYP1A2
inhibitors. See lit.
